Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated
